Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria.
COVID19
Neutralizing activity
VOCs
mAbs
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
02
2022
accepted:
14
06
2022
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
In patients with mild-to-moderate COVID-19 and at high risk of progression, casirivimab/imdevimab and bamlanivimab/etesivimab were utilized in Umbria from late April to November 2021. This period was characterized by an initial prevalence of alpha (B1.1.1.7) and its progressive substitution with the delta variant (B1.617.2). Many delta infections occurred in patients already recently vaccinated.Our study aimed to observe the clinical outcome of patients treated with mAbs associations in a subgroup in which viral isolation was obtained, the pre and post-infusion neutralizing antibody activity against their viral isolate. In this retrospective observational study, the clinical outcome before and 30 days after infusion, the baseline neutralizing activity of sera against their viral isolate, and the titers of neutralizing antibodies (NAbTs) one-hour post-infusion relative to the type of mAbs associations were evaluated. Better efficacy of the mAbs combinations relative to monotherapy regarding global hospitalization ( Alpha infections occurred prevalently in unvaccinated patients or after 5-6 months, while delta infections prevailed in vaccinated ones. A poor neutralizing activity in most of these patients was seen. A higher NAbT after infusion of casirivimab/imdevimab was observed.
Sections du résumé
Background and Objective
UNASSIGNED
In patients with mild-to-moderate COVID-19 and at high risk of progression, casirivimab/imdevimab and bamlanivimab/etesivimab were utilized in Umbria from late April to November 2021. This period was characterized by an initial prevalence of alpha (B1.1.1.7) and its progressive substitution with the delta variant (B1.617.2). Many delta infections occurred in patients already recently vaccinated.Our study aimed to observe the clinical outcome of patients treated with mAbs associations in a subgroup in which viral isolation was obtained, the pre and post-infusion neutralizing antibody activity against their viral isolate.
Methods
UNASSIGNED
In this retrospective observational study, the clinical outcome before and 30 days after infusion, the baseline neutralizing activity of sera against their viral isolate, and the titers of neutralizing antibodies (NAbTs) one-hour post-infusion relative to the type of mAbs associations were evaluated.
Results
UNASSIGNED
Better efficacy of the mAbs combinations relative to monotherapy regarding global hospitalization (
Conclusions
UNASSIGNED
Alpha infections occurred prevalently in unvaccinated patients or after 5-6 months, while delta infections prevailed in vaccinated ones. A poor neutralizing activity in most of these patients was seen. A higher NAbT after infusion of casirivimab/imdevimab was observed.
Identifiants
pubmed: 35865399
doi: 10.4084/MJHID.2022.050
pii: mjhid-14-1-e2022050
pmc: PMC9266464
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2022050Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Pharmaceuticals (Basel). 2021 Dec 06;14(12):
pubmed: 34959672
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
J Infect. 2021 Oct;83(4):467-472
pubmed: 34320390
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Mediterr J Hematol Infect Dis. 2021 Nov 01;13(1):e2021061
pubmed: 34804435
Infect Dis Ther. 2021 Dec;10(4):2479-2488
pubmed: 34435337
Viruses. 2021 Mar 05;13(3):
pubmed: 33807521